Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program

Executive Summary

AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories

You may also be interested in...



GSK and Targacept partners in pain

GlaxoSmithKline will gain access to Targacept's two lead candidates for pain: TC-2696, currently in a Phase II post-operative pain study in molar extraction patients, and TC-6499, a preclinical candidate for neuropathic pain, under a deal announced July 27. Partnership includes drugs targeting neuronal nicotinic receptors spanning five therapeutic areas, which also include smoking cessation, obesity, addiction and Parkinson's disease. Deal has a potential value of $1.5 million in addition to an upfront payment of $35 million. Program will be overseen by GSK's Center of Excellence for External Drug Discovery, with Targacept responsible for development of candidates through Phase II proof of concept. AstraZeneca has also partnered with Targacept on an NNR candidate for Alzheimer's, which is in Phase IIb (1"The Pink Sheet," Feb. 6, 2006, p. 19)...

GSK and Targacept partners in pain

GlaxoSmithKline will gain access to Targacept's two lead candidates for pain: TC-2696, currently in a Phase II post-operative pain study in molar extraction patients, and TC-6499, a preclinical candidate for neuropathic pain, under a deal announced July 27. Partnership includes drugs targeting neuronal nicotinic receptors spanning five therapeutic areas, which also include smoking cessation, obesity, addiction and Parkinson's disease. Deal has a potential value of $1.5 million in addition to an upfront payment of $35 million. Program will be overseen by GSK's Center of Excellence for External Drug Discovery, with Targacept responsible for development of candidates through Phase II proof of concept. AstraZeneca has also partnered with Targacept on an NNR candidate for Alzheimer's, which is in Phase IIb (1"The Pink Sheet," Feb. 6, 2006, p. 19)...

J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths

Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors

Related Content

UsernamePublicRestriction

Register

PS046826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel